Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival - PubMed (original) (raw)

Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival

L Qin et al. J Exp Med. 1994.

Abstract

Indefinite graft survival was obtained with murine cardiac allografts using the combined administration of monoclonal antibodies (mAbs) directed against the receptor ligand pair CD2-CD48. Although each antibody could prolong graft survival when given alone, neither resulted in the indefinite graft survival seen with the combination. Combined mAb administration is associated with inhibition of T cell priming and help and subsequent cytotoxic T lymphocyte generation. This indicates that the interaction between CD2 and its ligand is important for antigen priming and recognition, and combined mAbs may prove to be a useful therapeutic regimen for transplantation.

PubMed Disclaimer

Similar articles

• Anti-CD2 and anti-CD3 monoclonal antibodies synergize to prolong allograft survival with decreased side effects.
  Chavin KD, Qin L, Lin J, Kaplan AJ, Bromberg JS. Chavin KD, et al. Transplantation. 1993 Apr;55(4):901-8. doi: 10.1097/00007890-199304000-00040. Transplantation. 1993. PMID: 8097344
• Anti-CD2 monoclonal antibodies synergize with FK506 but not with cyclosporine or rapamycin to induce tolerance.
  Chavin KD, Qin L, Woodward JE, Lin J, Bromberg JS. Chavin KD, et al. Transplantation. 1994 Mar 15;57(5):736-40. doi: 10.1097/00007890-199403150-00017. Transplantation. 1994. PMID: 7511258
• Anti-CD48 (murine CD2 ligand) mAbs suppress cell mediated immunity in vivo.
  Chavin KD, Qin L, Lin J, Woodward J, Baliga P, Kato K, Yagita H, Bromberg JS. Chavin KD, et al. Int Immunol. 1994 May;6(5):701-9. doi: 10.1093/intimm/6.5.701. Int Immunol. 1994. PMID: 7521667
• The biology of human CD2.
  Reinherz EL, Chang HC, Clayton LK, Gardner P, Howard FD, Koyasu S, Jin YJ, Moingeon P, Sayre PH. Reinherz EL, et al. Cold Spring Harb Symp Quant Biol. 1989;54 Pt 2:611-25. doi: 10.1101/sqb.1989.054.01.073. Cold Spring Harb Symp Quant Biol. 1989. PMID: 2577023 Review. No abstract available.
• Analysis of the structure and interactions of CD2.
  Davis SJ, Jones EY, Bodian DL, Barclay AN, van der Merwe PA. Davis SJ, et al. Biochem Soc Trans. 1993 Nov;21(4):952-8. doi: 10.1042/bst0210952. Biochem Soc Trans. 1993. PMID: 7907562 Review. No abstract available.

Cited by

• 2B4, the natural killer and T cell immunoglobulin superfamily surface protein, is a ligand for CD48.
  Brown MH, Boles K, van der Merwe PA, Kumar V, Mathew PA, Barclay AN. Brown MH, et al. J Exp Med. 1998 Dec 7;188(11):2083-90. doi: 10.1084/jem.188.11.2083. J Exp Med. 1998. PMID: 9841922 Free PMC article.
• CD48-deficient mice have a pronounced defect in CD4(+) T cell activation.
  González-Cabrero J, Wise CJ, Latchman Y, Freeman GJ, Sharpe AH, Reiser H. González-Cabrero J, et al. Proc Natl Acad Sci U S A. 1999 Feb 2;96(3):1019-23. doi: 10.1073/pnas.96.3.1019. Proc Natl Acad Sci U S A. 1999. PMID: 9927686 Free PMC article.
• CCR7 and CD48 as Predicted Targets in Acute Rejection Related to M1 Macrophage after Pediatric Kidney Transplantation.
  Zhang J, Pei J, Yu C, Luo J, Hong Y, Hua Y, Wei G. Zhang J, et al. J Immunol Res. 2024 Jun 24;2024:6908968. doi: 10.1155/2024/6908968. eCollection 2024. J Immunol Res. 2024. PMID: 38957433 Free PMC article.
• Distinct regulatory roles of lymphocyte costimulatory pathways on T helper type-2 mediated autoimmune disease.
  Biancone L, Andres G, Ahn H, Lim A, Dai C, Noelle R, Yagita H, De Martino C, Stamenkovic I. Biancone L, et al. J Exp Med. 1996 Apr 1;183(4):1473-81. doi: 10.1084/jem.183.4.1473. J Exp Med. 1996. PMID: 8666905 Free PMC article.
• Anti-CD48 Monoclonal Antibody Attenuates Experimental Autoimmune Encephalomyelitis by Limiting the Number of Pathogenic CD4+ T Cells.
  McArdel SL, Brown DR, Sobel RA, Sharpe AH. McArdel SL, et al. J Immunol. 2016 Oct 15;197(8):3038-3048. doi: 10.4049/jimmunol.1600706. Epub 2016 Aug 31. J Immunol. 2016. PMID: 27581174 Free PMC article.

References

1. 1. FASEB J. 1991 Jun;5(9):2292-9 - PubMed
2. 1. J Exp Med. 1991 Nov 1;174(5):957-67 - PubMed
3. 1. Transplantation. 1971 Mar;11(3):298-302 - PubMed
4. 1. J Immunol. 1976 Mar;116(3):868-75 - PubMed
5. 1. J Exp Med. 1979 Jan 1;149(1):273-8 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Ovid Technologies, Inc.
  • PubMed Central
  • Silverchair Information Systems

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal